About the Lymphoma Program
As the only stand-alone pediatric lymphoma program in the country, the Lymphoma Program at Texas Children’s Cancer Center offers unparalleled care, access to clinical trials and innovative therapies for children with lymphoma and lymphoproliferative disorders.
Our multidisciplinary team of experts in pediatric oncology, surgery, pharmacology, stem cell transplant, molecular oncology, and cell and gene therapy works together to research and provide new means of diagnosing, monitoring, treating, preventing as well as predicting the behavior of lymphoma.
Our mission is to develop targeted therapies and protocols for the majority of patients using an individualized approach. While we participate in Children’s Oncology Group (COG) trials, we also assist patients who for whatever reason do not qualify for these trials. Ultimately, we want to design ways to minimize side effects from treatment so that children can have healthier lives.
Some of the many conditions we treat are:
- Anaplastic large cell lymphoma
- Auto-immune lymphoproliferative disease (ALPS)
- B cell lymphomas including Diffuse large B cell lymphoma
- Burkitt’s Lymphoma
- Chronic Active EBV (CAEBV)
- EBV-(Epstein-Barr virus) related lymphoma and lymphoproliferative disorders
- Hodgkin’s Lymphoma (Hodgkin’s Disease)
- Lymphadenopathy (enlarged lymph nodes)
- T cell and NK/T cell lymphomas
- AIDs-related lymphoma
- and other white blood cell disorders
The Lymphoma Program conducts numerous clinical trials for children with newly diagnosed lymphomas and for children with recurrent or resistant lymphoma.
The Lymphoma Program is dedicated to the integration of laboratory and clinical research to increase our understanding of lymphoma and to develop new, more effective therapies for these conditions. The principal areas of research focus on understanding the genetic determinants of tumor biology, exploiting the relationship of lymphoma with the immune system to develop immunotherapy and in new drug development. We are part of a National Cancer Institute-funded Specialized Programs of Research Excellence (SPORE) grant and participate in Children’s Oncology Group and internal lymphoma studies within Texas Children’s Cancer Center and the Cell and Gene Therapy Program.